LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

2.22 -3.9

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.21

Massimo

2.25

Metriche Chiave
By Trading Economics
Entrata	14M -1M
Vendite	16M 21M
Margine di Profitto	-4.943
Dipendenti	81
EBITDA	14M -996K

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+80.72% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	316M 1B
Apertura precedente	6.12
Chiusura precedente	2.22

Notizie sul Sentiment di mercato

By Acuity

31%

69%

61 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

0.6863 / 0.72 Supporto e resistenza

Lexicon Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 mag 2026, 23:53 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mag 2026, 23:50 UTC

Discorsi di Mercato

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mag 2026, 23:36 UTC

Discorsi di Mercato

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mag 2026, 23:07 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Share Sale Agreements Entered With Singland Properties

17 mag 2026, 23:05 UTC

Acquisizioni, Fusioni, Takeovers

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mag 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire Stake for $389 Million

17 mag 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mag 2026, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mag 2026, 15:26 UTC

Acquisizioni, Fusioni, Takeovers

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mag 2026, 08:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Lexicon Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

80.72% in crescita

Previsioni per 12 mesi

Media 4.03 USD 80.72%

Alto 6 USD

Basso 1 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Lexicon Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.6863 / 0.72Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

61 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.